Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.

P BalsasA Esteve-ArenysJ RoldánL JiménezV RodríguezJ G ValeroA Chamorro-JorganesR Puig de la BellacasaJ TeixidóA Matas-CéspedesA MorosA MartínezE CampoA Sáez-BorderíasJ I BorrellP Pérez-GalánD ColomerGael Roué

Published in: Journal of hematology & oncology (2017)

These results define IQS019 as a potential drug candidate for a variety of B lymphoid neoplasms, including cases with acquired resistance to current BCR-targeting therapies.

Keyphrases

acute lymphoblastic leukemia
chronic myeloid leukemia
tyrosine kinase
cell therapy
human health
adverse drug
emergency department
drug induced
mesenchymal stem cells
climate change